

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Bayzed Health Group Inc
佰澤醫療集團

(Incorporated in Cayman Islands with limited liability)

(Stock Code: 2609)

VOLUNTARY ANNOUNCEMENT STRATEGIC COOPERATION WITH MEINIAN HEALTH

This announcement is made by Bayzed Health Group Inc (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company of the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, on May 18, 2026, Bayzed Medical Investment Group Company Limited* (佰澤醫療投資集團有限公司), a wholly owned subsidiary of the Company and Meinian Da Jiankang (Group) Co., Ltd. (美年大健康產業(集團)有限公司) (“**Meinian Health**”), a subsidiary of Meinian Onehealth Healthcare Holdings Co., Ltd. (美年大健康產業控股股份有限公司), a company listed on the Shenzhen Stock Exchange with stock code: 002044.SZ) entered into a strategic cooperation agreement (the “**Strategic Cooperation Agreement**”). Leveraging their respective strengths and resources, the parties will jointly promote, on a nationwide basis, the establishment of an integrated, full-cycle health management service system covering “prevention – screening – diagnosis and treatment – rehabilitation”.

Pursuant to the Strategic Cooperation Agreement, the parties intend to carry out in-depth cooperation in the following areas:

- (i) **Brand and business synergies:** The parties will establish dedicated “Baihui Early Screening” branded zones at eligible health check-up centers under Meinian Health and jointly launch co-branded health check-up packages covering services such as painless gastroscopy and colonoscopy, liver elastography testing, and remote interpretation by specialists, with a view to enhancing early identification capabilities for major diseases;

- (ii) **Client referrals and service integration:** For clients who are found, during Meinian Health’s health check-ups, to have suspected lesions or to require multidisciplinary consultation (MDT), subject to the clients’ informed consent, their health information will be prioritized for referral through compliant channels to medical institutions designated by the Group, where they may access a green channel and MDT consultation services;
- (iii) **Data interoperability and platform collaboration:** On the basis of strict compliance with laws and regulations such as the Personal Information Protection Law of the People’s Republic of China, and upon obtaining clients’ separate and explicit authorization, the parties will explore compliant mechanisms for sharing health data to support precision health management and the delivery of continuous services; and
- (iv) **Sharing of medical and healthcare resources:** The parties will establish an expert resource collaboration mechanism to promote efficient allocation of quality medical resources and coordinated service delivery.

The Board is of the view that this cooperation represents an important milestone in the Group’s implementation of its “eight-ring” service framework of “prevention, screening, diagnosis, treatment, rehabilitation, management, connectivity and companionship”, and will help strengthen the Group’s execution capabilities for its “H@H” (Hospital at Home) service model. By integrating the Group’s professional expertise in precision oncology diagnosis and treatment, surgical treatment, and rehabilitation management with Meinian Health’s extensive health check-up network, substantial health data resources, and broad client base, the parties will jointly build a replicable and sustainable new ecosystem for health management. As such, the Board believes that the cooperation is in the interests of the Company and its shareholders as a whole and will be conducive to expanding the Group’s service coverage, enhancing brand influence, and promoting broader access to quality medical resources.

Meanwhile, the cooperation will also bring multiple benefits to Meinian Health, including: extending its service chain from the delivery of health check-up reports to subsequent diagnosis, treatment, and rehabilitation management, thereby enhancing client retention; launching higher value-added co-branded products to improve average revenue per client and gross margin structure; establishing a clear and professional specialist referral pathway to reinforce its authoritative image in the field of major disease prevention; and enabling the redeployment of human resources during off-peak periods to optimize operational efficiency. To the best of the knowledge, information and belief of the Directors, having made all reasonable enquiries, Meinian Health and its ultimate beneficial owners are third parties

independent of and not connected with the Company and its connected persons as defined under the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The entering into of the Strategic Cooperation Agreement does not constitute a notifiable transaction of the Company under Chapter 14 of the Listing Rules and shall not be subject to reporting, announcement and independent shareholders’ approval requirements under the Listing Rules.

The Board wishes to emphasise that the implementation of the strategic cooperation lays the foundation for a long-term strategic partnership between the parties thereto, such cooperation will be subject to the execution of appropriate definitive agreement(s).

The Board wishes to further emphasise that as at the date of this announcement, no definitive agreement in relation to any specific project under the strategic cooperation has been entered into by the parties or the Company. As such, the strategic cooperation may or may not be materialised. In the event that any specific project under the strategic cooperation materialises, the Company will comply with the relevant requirements under the Listing Rules and make further disclosure in accordance with all the applicable requirements as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Bayzed Health Group Inc
(佰澤醫療集團)
Dr. Chen Haoyang
Chairman and Executive Director

Hong Kong, May 18, 2026

As at the date of this announcement, the Board comprises executive Directors of Dr. Chen Haoyang, Mr. Zhao Yongkai, Ms. Xu Xu, Mr. Lu Jizhong and Mr. Feng Yu; and independent non-executive Directors of Mr. Chan Hok Leung, Ms. Liu Shuang and Dr. Guo Wei.